155 related articles for article (PubMed ID: 3162677)
1. Inhibition of amino acid uptake and incorporation into proteins in Friend erythroleukemia cells by the anthracycline antitumor antibiotic aclacinomycin A.
Schaefer A; Boldt J; Westendorf J; Steinheider G; Marquardt H
Biochem Pharmacol; 1988 Apr; 37(7):1377-82. PubMed ID: 3162677
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationship between anthracycline-induced differentiation and inhibition of glycoprotein synthesis in Friend erythroleukemia cells.
Schaefer A; Dahle M; Radenz G; Steinheider G; Marquardt H
Leukemia; 1991 Feb; 5(2):95-100. PubMed ID: 2020200
[TBL] [Abstract][Full Text] [Related]
3. Induction of erythroid differentiation by the anthracycline antitumor antibiotics, aclacinomycin A, musettamycin and marcellomycin.
Steinheider G; Westendorf J; Marquardt H
Leuk Res; 1986; 10(10):1233-9. PubMed ID: 3464812
[TBL] [Abstract][Full Text] [Related]
4. Induction of erythroid differentiation by the anthracycline antitumor antibiotic pyrromycin.
Steinheider G; Schaefer A; Westendorf J; Marquardt H
Cell Biol Toxicol; 1988 Mar; 4(1):123-33. PubMed ID: 3228706
[TBL] [Abstract][Full Text] [Related]
5. Effect of anthracycline analogues on the appearance of newly synthesized total RNA and messenger RNA in the cytoplasm of erythroleukemia cells.
Long BH; Willis CE; Prestayko AW; Crooke ST
Mol Pharmacol; 1982 Jul; 22(1):152-7. PubMed ID: 6956804
[TBL] [Abstract][Full Text] [Related]
6. Induction of differentiation in Friend-erythroleukemia cells by aclacinomycin A: early transient decrease in c-myc and c-myb mRNA levels.
Schaefer A; Dressel A; Lingelbach K; Schmidt CA; Steinheider G; Marquardt H
Leukemia; 1992 Aug; 6(8):828-33. PubMed ID: 1640736
[TBL] [Abstract][Full Text] [Related]
7. Induction of chromosomal aberrations by the anthracycline antitumor antibiotics N,N-dimethyldaunomycin and aclacinomycin A.
Steinheider G; Westendorf J; Marquardt H
Experientia; 1987 May; 43(5):586-8. PubMed ID: 3472901
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationships for the induction of differentiation of HL-60 human acute promyelocytic leukemia cells by anthracyclines.
Schwartz EL; Sartorelli AC
Cancer Res; 1982 Jul; 42(7):2651-5. PubMed ID: 6952957
[TBL] [Abstract][Full Text] [Related]
9. Studies on aclacinomycin A resistance in mouse lymphoblastoma.
Nishimura T; Suzuki H; Muto K; Tanaka Y; Tanaka N
J Antibiot (Tokyo); 1980 Jul; 33(7):737-43. PubMed ID: 6931828
[TBL] [Abstract][Full Text] [Related]
10. Decreased resistance to N,N-dimethylated anthracyclines in multidrug-resistant Friend erythroleukemia cells.
Schaefer A; Westendorf J; Lingelbach K; Schmidt CA; Mihalache DL; Reymann A; Marquardt H
Cancer Chemother Pharmacol; 1993; 31(4):301-7. PubMed ID: 8422694
[TBL] [Abstract][Full Text] [Related]
11. Fate of aclacinomycin-A and its metabolites effect on cell growth and macromolecular synthesis.
Fourcade A; Farhi JJ; Bennoun M; Goldschmidt E; Tapiero H
Biochem Pharmacol; 1983 Jun; 32(12):1819-24. PubMed ID: 6576787
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of glycoprotein biosynthesis by the inducers of HL-60 cell differentiation, aclacinomycin A and marcellomycin.
Morin MJ; Sartorelli AC
Cancer Res; 1984 Jul; 44(7):2807-12. PubMed ID: 6327026
[TBL] [Abstract][Full Text] [Related]
13. Dinaline inhibits amino acid transport and proliferation of colon carcinoma cells in vitro.
Schaider H; Haberkorn U; Stöhr M; Berger MR
Anticancer Res; 1995; 15(6B):2501-9. PubMed ID: 8669814
[TBL] [Abstract][Full Text] [Related]
14. Uptake, efflux, and hydrolysis of aclacinomycin A in Friend leukemia cells.
Fourcade A; Farhi JJ; Bennoun M; Tapiero H
Cancer Res; 1982 May; 42(5):1950-4. PubMed ID: 6950813
[TBL] [Abstract][Full Text] [Related]
15. Tumorigenicity in vivo and induction of mutagenesis and DNA repair in vitro by aclacinomycin A and marcellomycin: structure-activity relationship and predictive value of short-term tests.
Westendorf J; Marquardt H; Ketkar MB; Mohr U; Marquardt H
Cancer Res; 1983 Nov; 43(11):5248-51. PubMed ID: 6352017
[TBL] [Abstract][Full Text] [Related]
16. Comparative nuclear and cellular incorporation of daunorubicin, doxorubicin, carminomycin, marcellomycin, aclacinomycin A and AD 32 in daunorubicin-sensitive and -resistant Ehrlich ascites in vitro.
Seeber S; Loth H; Crooke ST
J Cancer Res Clin Oncol; 1980; 98(2):109-18. PubMed ID: 6938517
[TBL] [Abstract][Full Text] [Related]
17. Mutagenicity of aclacinomycin A and daunomycin derivatives.
Umezawa K; Sawamura M; Matsushima T; Sugimura T
Cancer Res; 1978 Jun; 38(6):1782-4. PubMed ID: 348304
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of some anthracycline antibiotics in an in vivo model for studying drug-induced human leukemia cell differentiation.
Schwartz EL; Brown BJ; Nierenburg M; Marsh JC; Sartorelli AC
Cancer Res; 1983 Jun; 43(6):2725-30. PubMed ID: 6573951
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of high volume intraperitoneal aclacinomycin-A (Aclarubicin).
Kerr IG; Archer S; DeAngelis C; Farrell S; Hanna S; McKee J
Invest New Drugs; 1987; 5(2):171-6. PubMed ID: 3477533
[TBL] [Abstract][Full Text] [Related]
20. Experimental studies of new anthracyclines: aclacinomycin, THP-adriamycin and ditrisarubicins.
Umezawa K; Kunimoto S; Takeuchi T
Biomed Pharmacother; 1987; 41(5):206-13. PubMed ID: 2444279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
